Under fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have reached an agreement that could see the policy reintroduced in the Biden administr
President Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines as part of the US administration's $1.75 trillion 'build back better' fram
The UK's Competition and Markets Authority (CMA) has resurrected a complaint against Pfizer and Flynn Pharma, claiming the two companies charged the NHS excessive prices for a widely-used e
Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer's therapy Aduhelm – but only if its assumptions on population size and uptake are differe
As post-pandemic recovery begins, big pharma remains in the spotlight. Jesse Mendelsohn explores pharma's priorities on pricing, profits and progress post-
The FDA "has failed in its responsibility to protect patients and families from unproven treatments with known harms" in approving Biogen's Alzheimer's disease drug Aduhelm.